Author

D. Niemeyer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 7 Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 10 Research Focus:host-pathogen & immune response· 8 Organism:human· 6 Research Focus:cell type annotation· 3 Research Focus:drug response / drug discovery· 3 Organism:mouse· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2

Frequent Co-Authors

C. Drosten· 9 shared V. Thiel· 5 shared A. Richter· 4 shared C. Goffinet· 4 shared S. Schroeder· 4 shared V. M. Corman· 4 shared J. Jansen· 3 shared J. Kazmierski· 3 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

9 shared papersMicrobiology

C. Drosten

Mutual co-authors in cluster

Author profile →

10 papers

Recent·Most cited

Antigenic cartography using variant-specific hamster sera reveals substantial antigenic variation among Omicron subvariants

B. Mühlemann, J. Trimpert, F. Walper, M. L. Schmidt, S. Schroeder, L. M. Jeworowski, J. Beheim-Schwarzbach, T. Bleicker, D. Niemeyer, J. M. Adler, R. M. Vidal, C. Langner, D. Vladimirova, D. J. Smith, M. Voss, , C. Drosten

The paper uses hamster sera from variant-specific infections to map antigenic differences among SARS-CoV-2 variants, revealing significant antigenic variation among Omicron subvariants.

bioRxiv · Jul 2, 2023Immunology

Pharmacological inhibition of bromodomain and extra-terminal proteins induces NRF-2-mediated inhibition of SARS-CoV-2 replication and is subject to viral antagonism

B. Mhlekude, D. Postmus, J. Weiner, S. Stenzel, F. J. Zapatero-Belinchon, R. Olmer, J. Jansen, A. Richter, J. Heinze, N. Heinemann, B. Muhlemann, S. Schroeder, T. C. Jones, M. A. Muller, C. Drosten, , C. Goffinet

This study shows JQ-1 inhibits SARS-CoV-2 replication via NRF-2 activation but is counteracted by viral antagonism, leading to transient antiviral effects.

bioRxiv · Sep 22, 2022 · PreprintMicrobiology

A live attenuated vaccine confers superior mucosal and systemic immunity to SARS-CoV-2 variants

G. Nouailles, J. M. Adler, P. Pennitz, S. Peidli, G. Teixeira Alves, M. Baumgart, J. Bushe, A. Voss, A. Langenhagen, F. Pott, J. Kazmierski, C. Goekeri, S. Simmons, N. Xing, C. Langner, , J. Trimpert

This study compares immune responses and efficacy of different SARS-CoV-2 vaccines in hamsters, finding that a live-attenuated vaccine provides superior protection against variants.

bioRxiv · May 16, 2022Immunology

Non-productive exposure of PBMCs to SARS-CoV-2 induces cell-intrinsic innate immunity responses

J. Kazmierski, K. Friedmann, D. Postmus, C. Fischer, J. Jansen, A. Richter, L. Bosquillon de Jarcy, C. Schüler, M. Sohn, S. Sauer, C. Drosten, A.-E. Saliba, L. Sander, D. Niemeyer, C. Goffinet

The paper shows that non-productive exposure of PBMCs to SARS-CoV-2 triggers JAK/STAT-dependent innate immune responses in monocytes, similar to those seen in mild COVID-19.

bioRxiv · Feb 15, 2022 · PreprintImmunology

Post-entry, spike-dependent replication advantage of B.1.1.7 and B.1.617.2 over B.1 SARS-CoV-2 in an ACE2-deficient human lung cell line

D. Niemeyer, S. Schroeder, K. Friedmann, F. Weege, J. Trimpert, A. Richter, S. Stenzel, J. Jansen, J. Emanuel, J. Kazmierski, F. Pott, L. M. Jeworowski, R. Olmer, M.-C. Jaboreck, B. Tenner, , C. Drosten

The paper shows that B.1.1.7 and B.1.617.2 SARS-CoV-2 variants have a replication advantage over B.1 in ACE2-deficient lung cells, suggesting reliance on alternative cellular factors.

bioRxiv · Oct 20, 2021 · PreprintMicrobiology

Enhanced fitness of SARS-CoV-2 variant of concern B.1.1.7, but not B.1.351, in animal models

L. Ulrich, N. J. Halwe, A. Taddeo, N. Ebert, J. Schön, C. Devisme, B. S. Trüeb, B. Hoffmann, M. Wider, M. Bekliz, M. Essaidi-Laziosi, M. L. Schmidt, D. Niemeyer, V. M. Corman, A. Kraft, , C. Benarafa

The paper compares the fitness of SARS-CoV-2 variants B.1.1.7 and B.1.351 in animal models, finding B.1.1.7 has a fitness advantage in ferrets and mice but not in hamsters.

bioRxiv · Jun 28, 2021Microbiology

Allicin inhibits SARS-CoV-2 replication and abrogates the antiviral host response in the Calu-3 proteome

K. Mösbauer, V. N. Fritsch, L. Adrian, J. Bernhardt, M. C. H. Gruhlke, A. J. Slusarenko, D. Niemeyer, H. Antelmann

This study shows allicin inhibits SARS-CoV-2 replication and suppresses the antiviral host response in Calu-3 cells.

bioRxiv · May 15, 2021 · PreprintMicrobiology

Analysis of SARS-CoV-2-controlled autophagy reveals spermidine, MK-2206, and niclosamide as putative antiviral therapeutics

N. C. Gassen, J. Papies, T. Bajaj, F. Dethloff, J. Emanuel, K. Weckmann, D. E. Heinz, N. Heinemann, M. Lennarz, A. Richter, D. Niemeyer, V. M. Corman, P. Giavalisco, C. Drosten, M. A. Muller

This study identifies spermidine, MK-2206, and niclosamide as potential antiviral therapeutics by enhancing autophagy against SARS-CoV-2 in vitro.

bioRxiv · Apr 15, 2020Microbiology

Efficient inactivation of SARS-CoV-2 by WHO-recommended hand rub formulations and alcohols

A. Kratzel, D. Todt, P. V'kovski, S. Steiner, M. L. Gultom, T. T. N. Thao, N. Ebert, M. Holwerda, J. Steinmann, D. Niemeyer, R. Dijkman, G. Kampf, C. Drosten, E. Steinmann, V. Thiel, S. Pfaender

The paper tests the virucidal activity of WHO-recommended hand rubs and alcohols against SARS-CoV-2, showing efficient inactivation for all tested products.

bioRxiv · Mar 10, 2020 · PreprintMicrobiology

Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform

T. T. N. Thao, F. Labroussaa, N. Ebert, P. V'kovski, H. Stalder, J. Portmann, J. Kelly, S. Steiner, M. Holwerda, A. Kratzel, M. Gultom, L. Laloli, L. Huesser, M. Wider, S. Pfaender, , V. Thiel

This paper describes a yeast-based synthetic genomics platform for rapid reconstruction of RNA viruses, including SARS-CoV-2, using synthetic DNA fragments and TAR cloning.

bioRxiv · Feb 21, 2020Microbiology